Citations

Clear

6055 citation(s) found for "Vu, Peter".

Autoimmune Encephalitis Is the Most Common Treatment-Responsive Cause of Rapidly Progressive Dementia; a Large Dutch Prospective Cohort Study. (PL4.002)
Steenhoven, Robin van, Bastiaansen, Daniëlle, Vries, Juna de, Jong, Frank Jan de , Satyadev, Nihal , Smitt, Peter Sillevis, Day, Gregory, Day, Gregory S. , Day, Gregory S , Bastiaansen, Daniëlle, Brenner, J , Kerstens, Jeroen , Crijnen, Y S , Seelaar, Harro , Titulaer, Maarten J

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210982 Get It

Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program
Lichtenstein, Gary R. , Allegretti, Jessica R. , Irving, Peter M., Charabaty, Aline , Kuehbacher, Tanja, Bananis, Eustratios , Woolcott, John , Dalam, Alexis B, Lazin, Krisztina , Keating, Michael J. , McDonnell, Aoibhinn , Danese, Silvio , Loftus, Edward V. , Banerjee, Rupa , Danese, Silvio

Mayo Clinic

Inflammatory Bowel Diseases | April 4, 2025 | Volume: 31 | Issue: 9 | Pages: 2352-2362

10.1093/ibd/izae308 | PMID 40184206 Get It

Abstract Background Patient age can impact the safety and efficacy of ulcerative colitis (UC) treatments. Etrasimod is an oral, once daily (QD), selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active UC. Here, we evaluate the impact of age on etrasimod safety and efficacy in patients with UC in the phase 3 ELEVATE UC clinical program. Methods Data were pooled from ELEVATE UC 52 and ELEVATE UC 12 in patients receiving etrasimod 2 mg QD or placebo. Proportions and incidence rates (IRs) per 100 patient-years of treatment-emergent adverse events (AEs) were stratified by age (<40, 40-59, and ≥60 years). With the same age stratifications, efficacy was evaluated in patients with baseline Modified Mayo scores of 5-9 and 4-9 for the primary efficacy endpoint (clinical remission) and secondary efficacy endpoints. Results Overall, 787 patients were enrolled (<40 years, n = 420 [53.4%]; 40-59 years, n = 276 [35.1%]; and ≥60 years, n = 91 [11.6%]). Arthralgia, fatigue, and hypertension IRs were higher in older patients, irrespective of treatment. Serious AEs and AEs leading to treatment discontinuation were low and consistent across age groups. Significantly more patients receiving etrasimod 2 mg QD vs placebo achieved efficacy endpoints, regardless of age. Conclusions The safety profile of etrasimod 2 mg QD in the ELEVATE UC population was consistent across age groups, with no change in the incidence of AEs. Patients receiving etrasimod vs placebo showed significant clinical benefit, regardless of age. ClinicalTrials.gov NCT03945188; NCT03996369.
Artificial Intelligence‐Enabled ECG : Physiologic and Pathophysiologic Insights and Implications
Kashou, Anthony H. , Siontis, Konstantinos C. , Adedinsewo, Demilade , Noseworthy, Peter A.

Mayo Clinic

Comprehensive Physiology | April 2, 2025 | Volume: 12 | Issue: 3 | Pages: 3417-3424

10.1002/j.2040-4603.2022.tb00218.x Get It

Abstract Advancements in machine learning and computing methods have given new life and great excitement to one of the most essential diagnostic tools to date—the electrocardiogram (ECG). The application of artificial intelligence‐enabled ECG (AI‐ECG) has resulted in the ability to identify electrocardiographic signatures of conventional and unique variables and pathologies, giving way to tremendous clinical potential. However, what these AI‐ECG models are detecting that the human eye is missing remains unclear. In this article, we highlight some of the recent developments in the field and their potential clinical implications, while also attempting to shed light on the physiologic and pathophysiologic features that enable these models to have such high diagnostic yield. © 2022 American Physiological Society. Compr Physiol 12:3417‐3424, 2022.
The diagnostic role of pharmacological provocation testing in cardiac electrophysiology: a clinical consensus statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC, t
Behr, Elijah R. , Winkel, Bo Gregers , Ensam, Bode , Alfie, Alberto , Arbelo, Elena , Berry, Colin , Conte, Giulio , Crotti, Lia , Corcia, M. Cecilia Gonzalez , Kaski, Juan Carlos , Schulze‐Bahr, Eric , Wilde, Arthur A.M. , Tfelt‐Hansen, Jacob , Wolpert, Christian, Cuesta, Alejandro, Damman, Peter, Dobrev, Dobromir, Drago, Fabrizio, Haugaa, Kristina, Krahn, Andrew, Krause, Ulrich, Lambiase, Pier D, Napolitano, Carlo, Odening, Katja E, Shimizu, Wataru, Veltmann, Christian, Lambiase, Pier D. , Odening, Katja E. , Cerrone, Marina , Conte, Giulio , Crotti, Lia , Kaski, Juan Carlos , Nademanee, Koonlawee , Postema, Pieter G , Priori, Silvia , Probst, Vincent , Sarquella-Brugada, Georgia , Schulze-Bahr, Eric , Tadros, Rafik , Wilde, Arthur A M , Tfelt-Hansen, Jacob , Behr, Elijah Raphael , Lambiase, Pier D , Odening, Katja E , Arbelo, Elena , Berry, Colin , Cerrone, Marina , Nademanee, Koonlawee , Postema, Pieter G. , Priori, Silvia G. , Tadros, Rafik , Wolpert, Christian, Cuesta, Alejandro, Damman, Peter, Dobrev, Dobromir, Drago, Fabrizio, Haugaa, Kristina, Krahn, Andrew, Krause, Ulrich, Napolitano, Carlo, Shimizu, Wataru, Veltmann, Christian

Mayo Clinic

Europace | April 1, 2025 | Volume: 27 | Issue: 4 | Pages: No page available

10.1093/europace/euaf067 | PMID 40165484 Get It

Abstract The pharmacological provocation test is a pivotal tool in cardiac electrophysiology for the diagnosis of potential causes of sudden cardiac death, sudden cardiac arrest (SCA), arrhythmias, symptoms, or ECG abnormalities. The 2022 European Society of Cardiology Guidelines for the Treatment of Ventricular Arrhythmias and Prevention of Sudden Cardiac Death offered guidance on provocation testing but did not describe the indications and requirements in depth. This clinical consensus statement, led by the European Heart Rhythm Association and approved by major international stakeholders, aims to advise the general cardiologist and the arrhythmia expert who to test and when, where, and how to do it. The statement focuses on current practice for the diagnosis of subclinical arrhythmia syndromes and the causes of SCA, building upon the recommendations of the Guidelines. We address the sodium channel blocker provocation test for patients suspected of Brugada syndrome as well as the use of epinephrine, isoproterenol, adenosine, ergonovine, and acetylcholine.
State of the Art of Artificial Intelligence in Clinical Electrophysiology in 2025: A Scientific Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), and the ESC Working Group on E-Cardiology
Svennberg, Emma , Han, Janet K. , Caiani, Enrico G. , Engelhardt, Sandy , Friedman, Paul A. , Garcia, Rodrigue , Ghanbari, Hamid , Hindricks, Gerhard , Man, Sharon , Hansen, Jacob Tfelt, Barker, Joseph, Casado-Arroyo, Ruben, Chatterjee, Neal A, Conte, Giulio, Diederichsen, Søren Zöga, Linz, Dominik, Mahtani, Arun Umesh, Zorzi, Alessandro, Tfelt‐Hansen, Jacob , Diederichsen, Søren Zöga , Ernst, Sabine , Friedman, Paul A , Garcia, Rodrigue , Hindricks, Gerhard , Man, Sharon H , Millet, José , Narayan, Sanjiv M , Ng, G. André , Noseworthy, Peter A , Tjong, Fleur V Y , Ramírez, Julia , Singh, Jagmeet P , Trayanova, Natalia A , Duncker, David , Tfelt-Hansen, Jacob , Diederichsen, Søren Z , Ernst, Sabine , Narayan, Sanjiv M. , Noseworthy, Peter A. , Ramírez, Julia , Trayanova, Natalia A. , Duncker, David , Barker, Joseph, Casado-Arroyo, Ruben, Chatterjee, Neal A, Conte, Giulio, Linz, Dominik, Mahtani, Arun Umesh, Zorzi, Alessandro

Mayo Clinic

Europace | March 31, 2025 | Volume: 27 | Issue: 5 | Pages: No page available

10.1093/europace/euaf071 | PMID 40163651 Get It

Abstract Aims Artificial intelligence (AI) has the potential to transform cardiac electrophysiology (EP), particularly in arrhythmia detection, procedural optimization, and patient outcome prediction. However, a standardized approach to reporting and understanding AI-related research in EP is lacking. This scientific statement aims to develop and apply a checklist for AI-related research reporting in EP to enhance transparency, reproducibility, and understandability in the field. Methods and results An AI checklist specific to EP was developed with expert input from the writing group and voted on using a modified Delphi process, leading to the development of a 29-item checklist. The checklist was subsequently applied to assess reporting practices to identify areas where improvements could be made and provide an overview of the state of the art in AI-related EP research in three domains from May 2021 until May 2024: atrial fibrillation (AF) management, sudden cardiac death (SCD), and EP lab applications. The EHRA AI checklist was applied to 31 studies in AF management, 18 studies in SCD, and 6 studies in EP lab applications. Results differed between the different domains, but in no domain reporting of a specific item exceeded 55% of included papers. Key areas such as trial registration, participant details, data handling, and training performance were underreported (<20%). The checklist application highlighted areas where reporting practices could be improved to promote clearer, more comprehensive AI research in EP. Conclusion The EHRA AI checklist provides a structured framework for reporting AI research in EP. Its use can improve understanding but also enhance the reproducibility and transparency of AI studies, fostering more robust and reliable integration of AI into clinical EP practice.
Interactions between genetic and epidemiological factors influencing mammographic density
Suger, Austin Hammermeister , Chen, Hongjie , Fan, Shaoqi , Bolla, Manjeet K. , Michailidou, Kyriaki , Wang, Qin , Fasching, Peter A. , Haeberle, Lothar, Aronson, Kristan J. , Eccles, Diana M, Evans, D. Gareth , Astley, Susan , Hall, Per, Pharoah, Paul D P, Antoniou, Antonis C, García‐Closas, Montserrat , González, Amy Berrington de , Easton, Douglas F. , Vachon, Celine M. , Lindström, Sara, Eccles, Diana , Fan, Shaoqi , Bolla, Manjeet K , Dennis, Joe , Michailidou, Kyriaki , Wang, Qin , Stone, Jennifer , Yadav, Siddhartha , Milne, Roger L , Norman, Aaron, Hall, Per N , Czene, Kamila , Pharoah, Paul D P , García-Closas, Montserrat , Easton, Doug , Eccles, Diana , Evans, D Gareth , Berrington de Gonzalez, Amy , Haas, Cameron B. , Scott, Christopher G. , Dunning, Alison M. , Stone, Jennifer , Gago-Domínguez, Manuela , Castelao, Jose E. , Murphy, Rachel A. , Couch, Fergus J. , Yadav, Siddhartha , Milne, Roger L. , Hopper, John L. , Norman, Aaron D. , Eliassen, A. Heather , Tapper, William , Czene, Kamila , Antoniou, Antonis C. , Gierach, Gretchen L. , Tamimi, Rulla M. , Vachon, Celine M. , Harrison, Tabitha A.

Mayo Clinic

American Journal of Epidemiology | March 30, 2025 | Volume: 195 | Issue: 5 | Pages: 1231-1241

10.1093/aje/kwaf067 | PMID 40153356 Get It

Abstract Studies have identified genetic and epidemiologic factors associated with mammographic density (MD) phenotypes. However, MD-associated genetic variants only account for a small proportion of the total estimated heritability. Interrogating interactions between genetic and epidemiologic factors could potentially identify additional MD-associated loci, expand our understanding of the genetic basis of MD phenotypes, and clarify how epidemiologic factors modulate relationships between genetic variants and MD. We conducted six separate genome-wide, gene–environment (GxE) interaction analyses, applying 2 degrees of freedom (df) and 1df interaction tests, for each of three MD phenotypes (percent density, dense area (DA), and nondense area (NDA)). The six epidemiologic factors considered were height, ever parous, parity, ever menopausal hormone therapy, ever breastfeeding, and months of breastfeeding. We included European ancestry participants from multiple studies within the Markers of Density consortium and the Breast Cancer Association Consortium (n = 4895-16 218 depending on specific analyses). We identified 11 loci with genome-wide significant (P < 5 × 10−8) interaction tests including two novel common genetic signals interacting with parity (8p21.2) and ever breastfeeding (19p13.2) for NDA. Our results suggest that epidemiologic risk factors might influence relationships between common genetic variants and MD phenotypes at particular genomic loci.
vNOTES as an Approach to Pelvic Surgery in the Hostile Abdomen
Pelle, A., Coombs, Peter, Cantave, M, Chen, A., Pelle, A., Coombs, P.

Mayo Clinic

Obstetrics & Gynecology | March 28, 2025 | Volume: 145 | Issue: 5S | Pages: 144S-144S

10.1097/aog.0000000000005851.242 Get It

Training and Performance of an Electrocardiogram-Enabled Machine Learning Model for Detection of Advanced Chronic Liver Disease
Rattan, Puru , Ahn, Joseph , Chara, Beatriz Sordi , Mullan, Aidan F. , Attia, Zachi I. , Friedman, Paul A. , Allen, Alina M. , Shah, Vijay H. , Kamath, Patrick S. , Ahn, Joseph C , Liu, Kan , Attia, Zachi I , Allen, Alina M , Kamath, Patrick S , Noseworthy, Peter A , Simonetto, Douglas A , Sordi Chara, Beatriz , Mullan, Aidan , Noseworthy, Peter A. , Simonetto, Douglas A.

Mayo Clinic

American Journal of Gastroenterology | March 28, 2025 | Volume: 120 | Issue: 10 | Pages: 2452-2456

10.14309/ajg.0000000000003433 | PMID 40146029 Get It

INTRODUCTION: Building on prior results, we hypothesized that an electrocardiogram (ECG)-enabled machine learning (ML) model could be used to detect advanced chronic liver disease (CLD). METHODS: A cohort with CLD and 12-lead ECGs was matched with controls from electronic health records. A ML model was trained as a binary classifier. RESULTS: There are 12,930 patients with CLD and 64,577 controls in the cohort. The model's discriminative ability to classify CLD showed an area under the receiver-operating characteristic curve 0.858 (95% confidence interval: 0.850–0.866), and at the chosen threshold, CLD ECGs had 12 times higher odds of being classified as CLD (diagnostic odds ratio 12.33, 95% confidence interval: 11.16–13.63). DISCUSSION: An ECG-enabled ML model affords great promise in identifying advanced CLD in low resource areas.
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement
Borate, Uma , Pugh, Kelly , Waller, Allyson, Welkie, Rina Li , Huang, Ying , Stahl, Maximilian , Platzbecker, Uwe , Wei, Andrew H. , Buckstein, Rena , Hasserjian, Robert P. , Fenaux, Pierre , Sallman, David A. , Nimer, Stephen D. , Little, Richard F. , Garcia‐Manero, Guillermo , Odenike, Olatoyosi, Kim, Tae Kon , Greenberg, Peter L. , Xu, Mina L. , Patnaik, Mrinal M. , Padron, Eric , Gore, Steven D. , Churpek, Jane E. , Bennett, John M., Brunner, Andrew M. , Zeidan, Amer M., Zeidan, Amer M. , Platzbecker, Uwe , Sekeres, Mikkael A , Wei, Andrew H , Roboz, Gail J , Loghavi, Sanam , Hasserjian, Robert P , Sallman, David A , Hourigan, Christopher S , Della Porta, Matteo Giovanni , Little, Richard F , Santini, Valeria , Taylor, Justin , Kim, Tae Kon , Halene, Stephanie , Komrokji, Rami S , Griffiths, Elizabeth A. , Greenberg, Peter L , Xie, Zhuoer , Sanz, Guillermo F , Patnaik, Mrinal , Carraway, Hetty E. , Boultwood, Jacqueline , Daver, Naval , Zeidan, Amer M , Churpek, Jane E , Bewersdorf, Jan Philipp , Dezern, Amy Elizabeth , Sekeres, Mikkael A. , Roboz, Gail J. , Savona, Michael R. , Loghavi, Sanam , Hourigan, Christopher S. , Santini, Valeria , Efficace, Fabio , Odenike, Olatoyosi , Komrokji, Rami S. , Xie, Zhuoer , Bejar, Rafael , Sanz, Guillermo , Figueroa, María E. , Abdel‐Wahab, Omar , Starczynowski, Daniel T. , Boultwood, Jacqueline , Daver, Naval , Majeti, Ravindra , List, Alan F. , Brunner, Andrew M., Churpek, Jane

Mayo Clinic

Blood | March 27, 2025 | Volume: 145 | Issue: 13 | Pages: 1369-1381

10.1182/blood.2023023717 | PMID 40146152 Get It

Abstract Excessively restrictive inclusion and exclusion criteria in clinical trials are one of many barriers to clinical trial enrollment for patients with myelodysplastic syndromes/neoplasms (MDSs). Many organizations are developing efforts to increase clinical trial eligibility; yet, several recent publications focused on patients with MDS suggest that many patients with this disease may be excluded from clinical trials unnecessarily. Clinical trial eligibility should reflect the phase of the study and risks of the agent being studied. Phase 3 trials should be less restrictive than early-phase trials to represent the real-world population as closely as possible. We hypothesize that many clinical trials, particularly phase 3 trials, have unnecessarily restrictive eligibility criteria. This study aims to evaluate the most common eligibility criteria according to phase of trial and to determine whether criteria correspond with drug safety signals. We identified MDS clinical trials registered on ClinicalTrials.gov from 1 January 2000 to 1 September 2023 and analyzed the eligibility criteria of 191 therapeutic MDS trials. We found that categorical inclusion and exclusion criteria are remarkably similar in representation across trial phases. Additionally, only 13% of trials are concordant with drug safety signals, suggesting that the eligibility criteria are often arbitrary. On behalf of the icMDS (International Consortium for Myelodysplastic Syndromes), an association of international MDS experts, we provide a position statement on restrictive eligibility criteria for MDS clinical trials that should be avoided with the aim of removing barriers to clinical trial enrollment.
Targeting senescence in Amyotrophic Lateral Sclerosis: senolytic treatment improves neuromuscular function and preserves cortical excitability in a TDP-43Q331K mouse model.
Viteri*, Jose A., Kerr*, Nathan R., Brennan*, Charles D., Kick, Grace Robinson , Wang, Meifang , Snyder, Harper K., Moore, Peter J., Darvishi, Fereshteh B. , Dashtmian, Anna R. , Ayyagari, Sindhuja N. , Rich, Kelly , Arnold, W. David, Zhu, Yi , Viteri*, Jose A., Kerr*, Nathan R., Brennan*, Charles D., Ketabforoush, Arsh Haj Mohamad Ebrahim , Snyder, Harper K., Moore, Peter J., Zhu, Yi , Arnold, W. David

Mayo Clinic

No container title available | March 27, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6081213/v1 | PMID 40196013 Get It

Abstract Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder marked by progressive motor neuron degeneration in the primary motor cortex (PMC) and spinal cord. Aging is a key factor in ALS onset and progression, with evidence suggesting that biological aging—a process involving cellular decline— far outpaces chronological aging in ALS. This promotes senescent cell accumulation—marked by irreversible cell-cycle arrest, impaired apoptosis, and chronic inflammation—disrupting tissue homeostasis and impairing neuronal support functions. Thus, targeting senescence presents a novel therapeutic strategy for ALS. Here, we investigated the senolytic combination Dasatinib and Quercetin (D&Q) in TDP-43 Q331K ALS mice. D&Q improved neuromuscular function and reduced plasma neurofilament light chain, a biomarker of axonal damage. The most pronounced improvement was the improved cortical excitability, accompanied by reductions in senescence and TDP-43 in the PMC. These findings highlight the potential of senolytics to mitigate ALS-related dysfunction, supporting their viability as a therapeutic strategy. *Jose A. Viteriab, Nathan R. Kerrab, and Charles D. Brennana are co-first authors.